SMS Pharmaceuticals
SMS Pharmaceuticals Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SMS Pharmaceuticals Ltd, framed against the sector median so the premium or discount is obvious at a glance.
SMS Pharmaceuticals Ltd trades at a P/E of 34.39× and P/B of 4.69×.
Valuation
Profitability
Growth
Financial Health
SMS Pharmaceuticals Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for SMS Pharmaceuticals Ltd, switchable between annual and quarterly views, consolidated or standalone.
SMS Pharmaceuticals Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,605.6 Cr and reported EPS of ₹11.15.
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 887 |
| Other Income | 3 | 5 | 3 | 5 | 5 | 4 | 6 | 8 |
| Total Income | 468 | 417 | 567 | 525 | 527 | 714 | 789 | 895 |
| Cost of Goods Sold (COGS) | 293 | 246 | 340 | 275 | 336 | 424 | 437 | 493 |
| Gross Profit | 172 | 166 | 223 | 244 | 186 | 285 | 346 | 394 |
| +Operating Expenses | 82 | 86 | 102 | 130 | 132 | 168 | 207 | 222 |
| EBITDA | 90 | 80 | 121 | 114 | 55 | 117 | 139 | 171 |
| +Non-Operating Expenses | 31 | 34 | 33 | 51 | 54 | 55 | 53 | 63 |
| Profit Before Tax (PBT) | 62 | 51 | 91 | 68 | 5 | 66 | 92 | 117 |
| +Tax Expense | 9 | 18 | 30 | 1 | 1 | 17 | 25 | 29 |
| Profit After Tax (PAT) | 53 | 33 | 63 | 62 | -7 | 50 | 69 | 102 |
| Earnings Per Share (EPS) | 6.31 | 3.86 | 7.39 | 7.35 | -0.83 | 5.89 | 7.80 | 10.90 |
| Diluted Shares Outstanding (Nos.) | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| +Additional Disclosures | 699 | 613 | 817 | 726 | 846 | 1,073 | 1,135 | 1,286 |
| Sales Growth % | — | -11.39 | 36.71 | -7.69 | 0.42 | 35.86 | 10.36 | 13.30 |
| YoY Sales Growth % | — | -11.39 | 36.71 | -7.69 | 0.42 | 35.86 | 10.36 | 13.30 |
| Material Cost % | 66 | 63 | 56 | 75 | 57 | 60 | 64 | 58 |
| Employee Cost % | 8 | 10 | 7 | 10 | 11 | 9 | 10 | 10 |
| Other Cost % | 10 | 11 | 11 | 15 | 15 | 15 | 16 | 15 |
| OPM % | 19 | 19 | 22 | 22 | 10 | 16 | 18 | 19 |
| Tax % | 14 | 36 | 33 | 1 | 27 | 26 | 27 | 25 |
| Profit Growth % | — | -38.84 | 91.28 | -0.49 | -111.35 | 805.82 | 38.75 | 47.52 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 71 | 58 | 99 | 82 | 22 | 85 | 105 | 131 |
SMS Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at SMS Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
SMS Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
SMS Pharmaceuticals Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy SMS Pharmaceuticals Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
SMS Pharmaceuticals Ltd's investment case rests on 9 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding consistently increased to 68.07% by September 2025.
Achieved 19.20% quarterly sales growth and 24.30% profit increase.
Low debt-to-equity ratio of 0.49 reduces financial risk.
Extensive export network spans approximately 75 countries worldwide.
Long-term EPS growth of 16.97% over the last five years.
What can break it.
ROCE at 12.50% and ROE at 11.80% are lower than peers.
P/E ratio of 36.90 is higher than the sector average.
Foreign Institutional Investor holding decreased from 0.63% to 0.28% by 2025.
Annual and quarterly cash flow per share is negative (-4.70).
The company currently has a 0.00% dividend yield.
What would change my mind.
Trim if P/E re-rates above 45. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 46.96. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 9%. The operating engine is no longer compounding capital efficiently.
SMS Pharmaceuticals Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SMS Pharmaceuticals Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
SMS Pharmaceuticals Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for SMS Pharmaceuticals Ltd — derived from the live tape, not yesterday's close.
SMS Pharmaceuticals Ltd last traded at ₹383.45 with an intraday range of ₹376.55–₹389.7 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹383.45| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 416.22 | +32.77 | +8.55% |
| R3 | 403.07 | +19.62 | +5.12% |
| R2 | 396.38 | +12.93 | +3.37% |
| R1 | 389.92 | +6.47 | +1.69% |
| PIVOT | 383.23 | -0.22 | -0.06% |
| CURRENT | 383.45 | — | — |
| S1 | 350.47 | -32.98 | -8.60% |
| S2 | 363.62 | -19.83 | -5.17% |
| S3 | 370.08 | -13.37 | -3.49% |
| S4 | 376.77 | -6.68 | -1.74% |
SMSPHARMA is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 383 ~ 389.7
Trading Inside opening range
SMS Pharmaceuticals Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SMS Pharmaceuticals Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SMS Pharmaceuticals Ltd stood at 34.5% of traded volume, against a 20-day average of 44.0%.
SMS Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings SMS Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SMS Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 119 documents below.
General Updates
SMS Pharmaceuticals Limited has informed the Exchange about General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
SMS Pharmaceuticals Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
SMS Pharmaceuticals Limited has informed the Exchange about Link of Recording
Copy of Newspaper Publication
SMS Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
SMS Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
General Updates
Investor Presentation
SMS Pharmaceuticals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in SMS Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.
SMS Pharmaceuticals insider activity below tracks 8 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| P. Manideep | Insider | 25 Feb 2026 | buy | +2.5 K | ₹10.11 L | ₹404.40 |
| P. Manideep | Insider | 25 Feb 2026 | buy | +2.5 K | ₹10.11 L | ₹404.40 |
| P. Manideep | Insider | 25 Feb 2026 | buy | +2.5 K | ₹10.11 L | ₹404.40 |
| Ramesh Babu Potluri | Insider | 27 Mar 2025 | buy | +25.00 L | ₹23.81 Cr | ₹95.25 |
| POTLURI INFRA PROJECTS LLP | Insider | 27 Mar 2025 | buy | +15.00 L | ₹14.29 Cr | ₹95.25 |
| Hima Bindu Potluri | Insider | 25 Mar 2025 | buy | +30.00 L | ₹68.3 Cr | ₹227.65 |
| POTLURI INFRA PROJECTS LLP | Insider | 25 Mar 2025 | buy | +73.46 L | ₹167.24 Cr | ₹227.65 |
| Potluri Laboratories Private Limited | Insider | 25 Mar 2025 | buy | +11.20 L | ₹25.5 Cr | ₹227.65 |
SMS Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SMS Pharmaceuticals has declared, sequenced by announce and record date.
SMS Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SMS Pharmaceuticals Ltd: business, sector, key facts.
What SMS Pharmaceuticals Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SMS Pharmaceuticals Ltd operates in the Healthcare, listed as NSE: SMSPHARMA, BSE: 532815.
SMS Pharmaceuticals Limited is an Indian pharmaceutical company specializing in the manufacturing and sale of active pharmaceutical ingredients (APIs) and their intermediates. Their operations span both domestic and international markets, demonstrating a significant global reach. The company boasts a diverse product portfolio catering to various therapeutic areas, showcasing a wide range of expertise in API development and production.
Their product offerings encompass a broad spectrum of therapeutic applications. This includes crucial medications for treating conditions such as retroviral infections (like HIV/AIDS), inflammation, viral infections, diabetes, fungal infections, epilepsy, migraines, blood clots, psychotic disorders, angina (chest pain), and ulcers. This breadth of therapeutic areas served indicates a commitment to addressing diverse healthcare needs across a substantial patient population.
Beyond their core API manufacturing and sales, SMS Pharmaceuticals also undertakes contract research, specifically focusing on peptide research. This demonstrates an investment in research and development, enabling the company to potentially expand its product offerings and strengthen its technological capabilities within the pharmaceutical sector. The contract research activities might also generate additional revenue streams and allow for collaborations with other research institutions or pharmaceutical companies.
The company's extensive export network, reaching approximately 75 countries globally, underscores its substantial international presence and market penetration. This highlights a successful strategy in establishing and maintaining relationships with international partners and distributors, thereby solidifying their position within the global pharmaceutical landscape. This broad export reach contributes significantly to the company's overall revenue and reinforces its reputation as a prominent player in the international API market.
Established in 1987 and headquartered in Hyderabad, India, SMS Pharmaceuticals has a long history in the pharmaceutical industry. This long-standing presence suggests a proven track record of consistent performance, regulatory compliance, and the establishment of robust operational processes within the competitive pharmaceutical manufacturing sector. Their continued success reflects adaptability to market changes and a strong commitment to meeting the evolving needs of the global healthcare community.
Questions investors ask about SMS Pharmaceuticals Ltd (SMSPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SMS Pharmaceuticals Ltd (SMSPHARMA)?
The current share price of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹383.45. Today, the stock has gained by ₹4.25 (1.12%), trading in a range of ₹376.55 to ₹389.7. The stock opened at ₹383 with a trading volume of 1,28,095 shares.
02Is SMS Pharmaceuticals Ltd stock a good investment for long-term?
SMS Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,605.6 crores, P/E ratio of 34.39, ROE of 14.31%, and ROCE of 12.50%. The dividend yield stands at 0.11%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SMS Pharmaceuticals Ltd stock?
The 52-week high price of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹0, while the 52-week low is ₹0. Currently trading at ₹383.45, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SMS Pharmaceuticals Ltd stock at the current price?
Whether to buy SMS Pharmaceuticals Ltd stock at ₹383.45 depends on multiple factors. The stock is currently trading with a P/E ratio of 34.39 and P/B ratio of 4.69. Today's performance shows a gain of 1.12%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SMS Pharmaceuticals Ltd and when is the next dividend?
SMS Pharmaceuticals Ltd offers a dividend yield of 0.11%, which means for every ₹100 invested at the current price of ₹383.45, you can expect to receive approximately ₹0.11 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 34.39, P/B Ratio: 4.69, ROE: 14.31%, ROCE: 12.50%, Dividend Yield: 0.11%, EPS: ₹11.15, Book Value: ₹81.83, and Debt-to-Equity: 46.46. The company's market cap stands at ₹3,605.6 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SMS Pharmaceuticals Ltd stock performing today in the market?
SMS Pharmaceuticals Ltd stock opened at ₹383 and is currently trading at ₹383.45, showing a gain of ₹4.25 (1.12%). The intraday high is ₹389.7 and low is ₹376.55. The trading volume stands at 1,28,095 shares, indicating moderate market participation today.
08What is the P/E ratio of SMS Pharmaceuticals Ltd and what does it indicate?
SMS Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 34.39, which means investors are willing to pay ₹34.39 for every ₹1 of earnings. With an EPS of ₹11.15, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SMS Pharmaceuticals Ltd (SMSPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy